Some unresolved issues with botulinum toxin.
Issues concerning botulinum toxin still need resolution in the laboratory and clinic. Assay nomenclature is unsatisfactory and attempts to establish common units and/or equivalents are misguided and dangerous. Optimum toxin concentrations for most indications are unknown. Loss of response is too readily ascribed to antibody formation. New therapeutic indications for toxin raise the possibility of additional mechanisms of action.
Guyer
B M
BM
DuoMed Limited, Medical Affairs Consultancy, 63 Moberly Road, Salisbury, Wilts, SP1 3BX, UK. bguyer@duomed.co.uk
D000818:Animals; D018726:Anti-Dyskinesia Agents / Q000276:immunology / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000276:immunology / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D006801:Humans; D007928:Lethal Dose 50; D008565:Membrane Proteins / Q000378:metabolism*; D009419:Nerve Tissue Proteins / Q000378:metabolism*; D050825:Synaptosomal-Associated Protein 25
D018726:Anti-Dyskinesia Agents; D008565:Membrane Proteins; D009419:Nerve Tissue Proteins; C494208:SNAP25 protein, human; D050825:Synaptosomal-Associated Protein 25; D001905:Botulinum Toxins